fbpx Skip to main content

Current Trends in Venture Funding: Perspective on Investments Post-Pandemic

When:

June 16, 2020 10:00 amJune 16, 2020 11:00 am (PDT)

Where:

Live Webinar

,

Registration Closed

Current Trends in Venture Funding: Perspective on Investments Post-Pandemic

Everyone in the life sciences industry has had to deal with a new reality after the pandemic hit. Clinical trial plans have been postponed, moving from in-person to virtual, adapting to a new normal. But through it all, life sciences experts are adapting to the new normal and continuing to be innovative. We’ll talk to a panel involving some experienced investors as they discuss managing investment opportunities in a new and different world.

Topics covered will span from perspective on the funding landscape to how to raise funds when face to face meetings are not feasible, what the future holds for VC funding, diligence, timing of an investment, and how each one of these funds are handling deal flow and adapting to the new environment.

Join us as we hear from experienced VCs discuss the topics mention above and get their perspectives.

Panelists:

User-added imageUser-added image
Karin Kleinhans, PhD, Investment Manager, Life Sciences Partners (LSP)

User-added imageUser-added image
Corey Goodman, PhD, Managing Partner, venBio Partners

User-added imageUser-added image
Andrew ElBardissi, MD, Partner, Deerfield


Moderated by:

User-added imageUser-added image
Laurie Halloran, Chief Executive Officer, Halloran Consulting

Sponsored by:
User-added image

Price of Admission

Biocom Member

Today’s Price: 0

Important Dates

Amount

Registration before

Registration before

Registration before

Registration cost

0

Refund before 2020-06-15

0

Refund before

Refund Before

Non-Member

Today’s Price: 0

Important Dates

Amount

Registration before

Registration before

Registration before

Registration cost

0

Refund before 2020-06-15

0

Refund before

Refund Before

  • Panelist’s Bios
    User-added image
    Karin Kleinhans, PhD, Investment Manager, Life Sciences Partners (LSP)

    Karin Kleinhans, PhD joined LSP in 2015 as Associate and became an Investment Manager in 2019. Karin is part of the LSP investment team focused on private companies, and is involved in all stages of the investment process. She has been involved in a large number of LSP’s investments and is a Board Director of Cardior and Board Observer of Endotronix and Lumeon. Prior to joining LSP, Karin was an associate in an international patent law firm where she was involved in all aspects of the patent life cycle for international clients from the biotech industry. Previously, she gained experience in clinical trials and regulatory affairs within pharmaceutical drug development. Before, Karin was a researcher at the Max-Planck Department for Stem Cell Aging and the Institute of Molecular Medicine at the University Ulm.  Karin received her PhD from the International Graduate School in Molecular Medicine in Ulm funded by the Excellence Initiative of the German Federal and States Governments. She was awarded her Bachelor`s and Master`s Degree in Molecular Medicine where she combined medical studies with scientific research training. Karin is a former all-star field hockey team player and lives in Munich with her husband. 

    User-added image
    Corey Goodman, PhD, Managing Partner, venBio Partners
    Corey Goodman is a scientist, educator, and entrepreneur. He spent 25 years as Professor of Biology at Stanford University and Evan Rauch Chair of Neurobiology at U.C. Berkeley (Dept. of Molecular and Cell Biology), where he was a Howard Hughes Medical Institute Investigator, Head of the Neurobiology Division, and co-founder and Director of the Wills Neuroscience Institute. He is currently Adjunct Professor of Neuroscience in the Wills Neuroscience Institute at U.C. Berkeley. Dr. Goodman is an elected member of the National Academy of Sciences, American Academy of Arts and Sciences, and American Philosophical Society, and recipient of many honors including the Alan T. Waterman Award, Canada Gairdner Biomedical Award, March-of-Dimes Prize in Developmental Biology, Reeve-Irvine Research Medal, and Dawson Prize in Genetics from Trinity College Dublin. Dr. Goodman co-founded seven biotechnology companies (the first being Exelixis), and led one of them (Renovis) as President and CEO from a private to public company until its acquisition. He was recruited to be President and founder of Pfizer’s Biotherapeutics and Bioinnovation Center and a member of Pfizer’s executive leadership team. Today, Dr. Goodman is a Managing Partner of venBio Partners LLC. He is Chair of the Board of ALX Oncology, Tollnine, and Second Genome. He is a member of the Board of Checkmate and NFlection. He chaired Labrys Biologics until its acquisition by Teva. Amongst his many public policy roles, Dr. Goodman is a member of the University of California Innovation Council, a member of the board of the Pacific Institute, and former Chair of both the California Council on Science and Technology (advising the California governor and state legislature) and the National Research Council’s (NAS) Board on Life Sciences (advising the federal government).

    Andrew ElBardissi, MD, Partner, Deerfield
    Andrew ElBardissi, M.D., is a Partner on the Medical Devices team at Deerfield and joined the Firm in 2017. Prior to Deerfield, Dr. ElBardissi was a Principal at Longitude Capital, where he focused on investments in medtech and biotechnology. Before that, he was an Associate in JPMorgan’s healthcare investment banking practice. Dr. ElBardissi received residency training in General Surgery at Harvard Medical School’s Brigham and Women’s Hospital and in Cardiothoracic Surgery at Stanford University. He has been independently funded by the National Institutes of Health and the Agency for Healthcare Research and Quality, has authored over 30 publications in leading peer-reviewed scientific journals and has presented his research at numerous medical and surgical conferences. Dr. ElBardissi holds an M.D. from the Mayo Clinic, an M.P.H. in Quantitative Methods from Harvard University, an M.B.A. from Harvard Business School and a B.S. with honors in Biology (Phi Beta Kappa) from the Schreyer Honors College at the Pennsylvania State University.

    Laurie Halloran, Chief Executive Officer, President, Halloran Consulting Group
    Laurie Halloran founded Halloran Consulting Group in 1998, originally operating out of an unfinished bathroom. Her time as a pediatric ICU nurse had inspired her to start a company that helps move new therapies through FDA processes to get them into the hands of patients desperately in need. By providing a strategic development team, innovative start-up companies could have access to world-class expertise at a fraction of the cost. Since its humble beginnings, Halloran has grown into a successful consultancy of like-minded experts who are dedicated to improving human health by making life science companies better at what they do. Laurie has been named 2018 Women’s Business Enterprise Star by the Women's Business Enterprise National Council (WBENC) and has won a 2017 Enterprising Women of the Year Award from Enterprising Women Magazine. Halloran Consulting Group was also named an Inc. 5000 Fastest Growing Company for the past three years in a row. In 2015, Laurie was honored by the Boston Business Journal as a Woman of Influence, in 2010 was selected as one of the 100 Most Inspiring People in Life Science by PharmaVoice, and in 2009, she was awarded Clinical Researcher of the Year by the New England Chapter of the Associate of Clinical Research Professionals. Laurie lectures at Boston University Medical School and the Tufts Center for Drug Development Post-Graduate program. She has previously taught at George Washington University and Harvard University.  Laurie earned a Bachelor of Science in nursing from Russell Sage College and a Master of Science in management from Lesley University. She is also a Prosci Certified Change Practitioner.

Registration Closed